REYATAZ atazanavir (as sulfate) 300mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

reyataz atazanavir (as sulfate) 300mg capsule bottle

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 341.69 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).